To the full analysis
Zimmer Biomet Holdings stock: growth
ZBHZimmer Biomet Holdings reported $8.23B in revenue for fiscal 2025, up 7.2% on the prior year, up 6.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
4.6%
per year from 2006 to 2025, per share 5.9%
Earnings (Annual rate)
−0.9%
per year from 2006 to 2025, per share 0.4%
Free cash flow (Annual rate)
3.5%
per year from 2006 to 2025, per share 4.7%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 6.1% | 3.2% | 4.6% |
| Revenue per share | 7.7% | 3.0% | 5.9% |
| Earnings | no data | 17.0% | −0.9% |
| Earnings per share | no data | 29.8% | 0.4% |
| Free cash flow | 6.2% | 8.0% | 3.5% |
| Free cash flow per share | 7.7% | 7.7% | 4.7% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $3.5B | $834.5M | $772.4M |
| 2007 | $3.9B | $773.2M | $753.2M |
| 2008 | $4.12B | $848.6M | $440.8M |
| 2009 | $4.1B | $717.4M | $852.9M |
| 2010 | $4.22B | $596.9M | $1.11B |
| 2011 | $4.45B | $760.8M | $1.06B |
| 2012 | $4.47B | $755M | $1.04B |
| 2013 | $4.62B | $761M | $863.1M |
| 2014 | $4.67B | $720.3M | $915.6M |
| 2015 | $6B | $147M | $682.1M |
| 2016 | $7.67B | $305.9M | $1.45B |
| 2017 | $7.8B | $1.81B | $1.43B |
| 2018 | $7.93B | −$379.2M | $1.58B |
| 2019 | $7.98B | $1.13B | $1.18B |
| 2020 | $6.13B | −$138.9M | $1.09B |
| 2021 | $6.83B | $401.6M | $1.35B |
| 2022 | $6.94B | $231.4M | $1.07B |
| 2023 | $7.39B | $1.02B | $1.19B |
| 2024 | $7.68B | $903.8M | $1.14B |
| 2025 | $8.23B | $705.2M | $1.47B |
Revenue by segment
How Zimmer Biomet Holdings, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Knees40%
- S E T26%
- Hips25%
- Other8%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Knees | $2.75B | $2.74B | $2.77B | $2.81B | $2.39B | $2.65B | $2.78B | $3.04B | $3.17B | $3.32B | 40.4% |
| S E T | $1.65B | $1.71B | $1.75B | $1.8B | $1.32B | $1.73B | $1.7B | $1.75B | $1.87B | $2.15B | 26.1% |
| Hips | $1.87B | $1.88B | $1.92B | $1.94B | $1.75B | $1.86B | $1.89B | $1.97B | $2B | $2.09B | 25.4% |
| Other | $1.4B | $1.48B | $1.49B | $1.44B | $665.2M | $595.5M | $570M | $636M | $640.3M | $665.5M | 8.1% |
| Total revenue | $7.67B | $7.8B | $7.93B | $7.98B | $6.13B | $6.83B | $6.94B | $7.39B | $7.68B | $8.23B | 100% |
Revenue by region
Where Zimmer Biomet Holdings, Inc. generates its revenue.
- Americas62%
- E M E A22%
- Asia Pacific15%
Figures as a table
| 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|
| Americas | $4.3B | $4.62B | $4.79B | $5.14B | 62.5% |
| E M E A | $1.46B | $1.59B | $1.69B | $1.83B | 22.2% |
| Asia Pacific | $1.19B | $1.18B | $1.19B | $1.26B | 15.3% |
| Total revenue | $6.94B | $7.39B | $7.68B | $8.23B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 29 Feb 2024)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.